Hosted on MSN25d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
Image Source: Zacks Investment Research Linvoseltamab is an investigational BCMAxCD3 bispecific antibody ... these oncology drugs should be a great boost for REGN. Last month, Regeneron reported ...
pharmaphorum9d
Regeneron’s cholesterol drug evinacumab claims February FDA date
which tested the antibody in 65 HoFH patients already being treated with statins, PCSK9 inhibitors and other drugs like ezetimibe. Adding in Regeneron’s antibody resulted in a 49% drop in ...
Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment
Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...
BioSpace9d
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...
Cancer Therapy Advisor5d
Linvoseltamab Under Review for Relapsed/Refractory Multiple Myeloma
The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.
Rheumatology Advisor12d
February 2025 Recap: Drug Pipeline Updates
The table is a review of notable updates that occurred in February 2025 for investigational products in development.
Fierce Biotech5d
Speed, Scale, and Success – The Rise of Bispecific Antibodies in Targeted Therapies
Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...
Yahoo Finance26d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
Regeneron’s shares have lost 30.5% in the past year compared with the medical-biomedical genetics industry’s decline of 6.7%. Linvoseltamab is an investigational BCMAxCD3 bispecific antibody ...